PD-L1 and tumor mutational burden (TMB)-based immunotherapeutic clinical trials have shown favorable results in a small subset of invasive breast cancer (IBC) patients, mainly triple-negative breast cancer (TNBC) patients8. This evidence concerns the gene CD274 and inflammatory breast carcinoma.